Perspective Q2 net loss widens to $11.1M on 17% revenue drop; pipeline advances

Perspective Therapeutics, Inc.

2024-Q2 EPS reported -$0.45 revenue$4,151,000

Q2 2023 revenue $2.1M (-17% YoY); net loss $11.1M vs $2.1M loss a year ago.
Cash and equivalents $28.5M at June 30, 2023, down from $43.9M at Dec 31, 2022.
Phase 1/2a trials initiated for VMT-α-NET (neuroendocrine) and VMT01 (melanoma); first patient dosed; preliminary data expected by end-2023.
New executives: Heidi Henson (Audit Chair), Andrew Bright (EVP Brachytherapy), Shane Cobb (EVP Operations).
Cesium-131 brachytherapy data showed 96% disease-free survival at 10 years for prostate cancer.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Perspective Therapeutics, Inc. reported financial results for second quarter of fiscal 2023 ended June 30, 2023.

Period: second quarter of fiscal 2023 ended June 30, 2023
Result: reported results

Exact text from the filing

On August 11, 2023, the Company issued a press release announcing its financial results for the second quarter of fiscal 2023 ended June 30, 2023, the text of which is attached hereto as Exhibit 99.1.

View on SEC.gov

38 earnings releases filed in the last 30 days. Browse all earnings releases →

Perspective Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-23-023162

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.